Role of Innate Immunity in Cancers and Antitumor Response

Chapter

Abstract

Innate immune system serves as the first line of defense against pathogens and cancers. In tumors, innate immune cells are attracted into the tumor site, where they can recognize the transformed cells. Recognition of tumor cells is mediated by receptors expressed on the surface of innate immune cells, such as NK receptors, CLRs, as well as phagocytosis receptors expressed on APCs. Additionally, factors released from stressed cells at the tumor microenvironment, such as PAMPs and DAMPs, are recognized by another set of receptors, including TLRs, RLRs, and NLRs, which trigger distinct innate signaling pathways; these pathways lead to maturation, activation, as well as production of cytokines and chemokines from immune cells, to attract more immune cells into the tumor site and initiate an immune response against tumor cells.

Innate immune cells may also be involved in the promotion of tumor growth, angiogenesis, and metastasis, due to the interaction between tumor cells and innate immune cells at the tumor microenvironment. Thus, a deep knowledge of the role of innate immune system in tumor immunity and tumorigenesis is critical to develop new strategies for the immunotherapy of cancer.

Keywords

Tyrosine Bacillus Sarcoma Oligomerization Interferon 

Notes

Acknowledgments

We apologize to the authors whose work could not be cited due to space constraints.

This study is partially supported by a Grant-in-Aid for Scientific Research and Scientific Research for Innovative Areas from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) and the Ministry of Health, Labour and Welfare, The Naito Foundation, and the Astellas Foundation for Research on Metabolic Disorders (M.J.).

References

  1. 1.
    Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124:263–6.PubMedGoogle Scholar
  2. 2.
    Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235–71.PubMedGoogle Scholar
  3. 3.
    Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today. 2000;21:455–64.PubMedGoogle Scholar
  4. 4.
    Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol. 2012;13:832–42.PubMedCentralPubMedGoogle Scholar
  5. 5.
    Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7:211–7.PubMedGoogle Scholar
  6. 6.
    Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol. 2002;3:999–1005.PubMedCentralPubMedGoogle Scholar
  7. 7.
    Zou W. Regulatory T, cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6:295–307.PubMedGoogle Scholar
  8. 8.
    Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med. 2001;193:661–70.PubMedCentralPubMedGoogle Scholar
  9. 9.
    Robertson MJ. Role of chemokines in the biology of natural killer cells. J Leukoc Biol. 2002;71:173–83.PubMedGoogle Scholar
  10. 10.
    Bottino C, Moretta L, Pende D, Vitale M, Moretta A. Learning how to discriminate between friends and enemies, a lesson from natural killer cells. Mol Immunol. 2004;41:569–75.PubMedGoogle Scholar
  11. 11.
    Sinkovics JG, Horvath JC. Human natural killer cells: a comprehensive review. Int J Oncol. 2005;27:5–47.PubMedGoogle Scholar
  12. 12.
    Johnsen AC, Haux J, Steinkjer B, Nonstad U, Egeberg K, Sundan A, et al. Regulation of APO-2 ligand/trail expression in NK cells-involvement in NK cell-mediated cytotoxicity. Cytokine. 1999;11:664–72.PubMedGoogle Scholar
  13. 13.
    Mirandola P, Ponti C, Gobbi G, Sponzilli I, Vaccarezza M, Cocco L, et al. Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. Blood. 2004;104:2418–24.PubMedGoogle Scholar
  14. 14.
    Gołab J. Interleukin 18-interferon γ inducing factor-a novel player in tumour immunotherapy? Cytokine. 2000;12:332–8.PubMedGoogle Scholar
  15. 15.
    Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L, et al. NK cells and cancer. J Immunol. 2007;178:4011–6.PubMedGoogle Scholar
  16. 16.
    Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285:727–9.PubMedGoogle Scholar
  17. 17.
    Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005;436:709–13.PubMedGoogle Scholar
  18. 18.
    Elliott JM, Wahle JA, Yokoyama WM. MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment. J Exp Med. 2010;207:2073–9.PubMedCentralPubMedGoogle Scholar
  19. 19.
    Smyth MJ, Thia KY, Cretney E, Kelly JM, Snook MB, Forbes CA, et al. Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol. 1999;162:6658–62.PubMedGoogle Scholar
  20. 20.
    Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med. 2002;195:335–41.PubMedCentralPubMedGoogle Scholar
  21. 21.
    Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S, et al. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol. 2005;43:1013–20.PubMedGoogle Scholar
  22. 22.
    Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med. 2002;195:327–33.PubMedCentralPubMedGoogle Scholar
  23. 23.
    Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural-killer cells and dendritic cells: “l’union fait la force”. Blood. 2005;106:2252–8.PubMedGoogle Scholar
  24. 24.
    Akazawa T, Ebihara T, Okuno M, Okuda Y, Shingai M, Tsujimura K, et al. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc Natl Acad Sci U S A. 2007;104:252–7.PubMedCentralPubMedGoogle Scholar
  25. 25.
    Boudreau JE, Stephenson KB, Wang F, Ashkar AA, Mossman KL, Lenz LL, et al. IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells. Cancer Res. 2011;71:2497–506.PubMedGoogle Scholar
  26. 26.
    Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol. 2003;21:483–513.PubMedGoogle Scholar
  27. 27.
    Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med. 2000;191:661–8.PubMedCentralPubMedGoogle Scholar
  28. 28.
    Singh AK, Wilson MT, Hong S, Olivares-Villagómez D, Du C, Stanic AK, et al. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med. 2001;194:1801–11.PubMedCentralPubMedGoogle Scholar
  29. 29.
    Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science. 1997;278:1623–6.PubMedGoogle Scholar
  30. 30.
    Gillessen S, Naumov YN, Nieuwenhuis EE, Exley MA, Lee FS, Mach N, et al. CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proc Natl Acad Sci U S A. 2003;100:8874–9.PubMedCentralPubMedGoogle Scholar
  31. 31.
    Akbari O, Faul JL, Hoyte EG, Berry GJ, Wahlström J, Kronenberg M, et al. CD4+ invariant T-cell-receptor natural killer T cells in bronchial asthma. N Engl J Med. 2006;354:1117–29.PubMedGoogle Scholar
  32. 32.
    Crowe NY, Coquet JM, Berzins SP, Kyparissoudis K, Keating R, Pellicci DG, et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med. 2005;202:1279–88.PubMedCentralPubMedGoogle Scholar
  33. 33.
    Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol. 2000;1:515–20.PubMedGoogle Scholar
  34. 34.
    Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD, et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells blocks cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med. 2003;198:1741–52.PubMedCentralPubMedGoogle Scholar
  35. 35.
    Hayday AC. Gamma delta cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol. 2000;18:975–1026.PubMedGoogle Scholar
  36. 36.
    Mortia CT, Mariuzza RA, Brenner MB. Antigen recognition by human gamma delta T cells: pattern recognition by the adaptive immune system. Springer Semin Immunopathol. 2000;22:191–217.Google Scholar
  37. 37.
    Wu Y, Wu W, Wong WM, Ward E, Thrasher AJ, Goldblatt D, et al. Human gamma delta T cells: a lymphoid lineage cell capable of professional phagocytosis. J Immunol. 2009;183:5622–9.PubMedGoogle Scholar
  38. 38.
    Girardi M, Glusac E, Filler RB, Roberts SJ, Propperova I, Lewis J, et al. The distinct contributions of murine T cell receptor (TCR) gamma-delta+ and TCR alpha-beta+ T cells to different stages of chemically induced skin cancer. J Exp Med. 2003;198:747–55.PubMedCentralPubMedGoogle Scholar
  39. 39.
    Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, et al. Regulation of cutaneous malignancy by gamma-delta T cells. Science. 2001;294:605–9.PubMedGoogle Scholar
  40. 40.
    Kabelitz D, Wesch D, He W. Perspectives of gamma delta T cells in tumor immunology. Cancer Res. 2007;67:5–8.PubMedGoogle Scholar
  41. 41.
    Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gamma-delta T cells. Science. 2005;309:264–8.PubMedGoogle Scholar
  42. 42.
    De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell. 2013;23:277–86.PubMedGoogle Scholar
  43. 43.
    Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39–51.PubMedGoogle Scholar
  44. 44.
    Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol. 2011;11:762–74.PubMedCentralPubMedGoogle Scholar
  45. 45.
    Goede V, Brogelli L, Ziche M, Augustin HG. Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int J Cancer. 1999;82:765–70.PubMedGoogle Scholar
  46. 46.
    Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B, et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res. 1999;59:4681–7.PubMedGoogle Scholar
  47. 47.
    Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16:2927–31.PubMedGoogle Scholar
  48. 48.
    Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, et al. Macrophage polarization in tumour progression. Semin Cancer Biol. 2008;18:349–55.PubMedGoogle Scholar
  49. 49.
    Bancroft GJ, Schreiber RD, Unanue ER. Natural immunity: a T-cell-independent pathway of macrophage activation, defined in the SCID mouse. Immunol Rev. 1991;124:5–24.PubMedGoogle Scholar
  50. 50.
    MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol. 1997;15:323–50.PubMedGoogle Scholar
  51. 51.
    Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11:889–96.PubMedGoogle Scholar
  52. 52.
    Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12:265–77.PubMedCentralPubMedGoogle Scholar
  53. 53.
    Conejo-Garcia JR, Benencia F, Courreges MC, Kang E, Mohamed-Hadley A, Buckanovich RJ, et al. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of VEGF-A. Nat Med. 2004;10:950–8.PubMedGoogle Scholar
  54. 54.
    Robinson RT, Khader SA, Martino CA, Fountain JJ, Teixeira-Coelho M, Pearl JE, et al. Mycobacterium tuberculosis infection induces il12rb1 splicing to generate a novel IL-12Rbeta1 isoform that enhances DC migration. J Exp Med. 2010;207:591–605.PubMedCentralPubMedGoogle Scholar
  55. 55.
    Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-Hogan M, et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res. 2004;64:5535–8.PubMedGoogle Scholar
  56. 56.
    Osman M, Tortorella M, Londei M, Quaratino S. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases define the migratory characteristics of human monocyte-derived dendritic cells. Immunology. 2002;105:73–82.PubMedCentralPubMedGoogle Scholar
  57. 57.
    Wobser M, Voigt H, Houben R, Eggert AO, Freiwald M, Kaemmerer U, et al. Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression. Cancer Immunol Immunother. 2007;56:1017–24.PubMedGoogle Scholar
  58. 58.
    Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF. Tumor-infiltrating gamma-delta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity. 2007;27:334–48.PubMedGoogle Scholar
  59. 59.
    Ebata K, Shimizu Y, Nakayama Y, Minemura M, Murakami J, Kato T, et al. Immature NK cells suppress dendritic cell functions during the development of leukemia in a mouse model. J Immunol. 2006;176:4113–24.PubMedGoogle Scholar
  60. 60.
    Lichtenstein AK, Berek J, Kahle J, Zighelboim J. Role of inflammatory neutrophils in antitumor effects induced by intraperitoneal administration of Corynebacterium parvum in mice. Cancer Res. 1984;44:5118–23.PubMedGoogle Scholar
  61. 61.
    Curcio C, Di Carlo E, Clynes R, Smyth MJ, Boggio K, Quaglino E, et al. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest. 2003;111:1161–70.PubMedCentralPubMedGoogle Scholar
  62. 62.
    Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol. 2003;21:3343–50.PubMedGoogle Scholar
  63. 63.
    Suttmann H, Riemensberger J, Bentien G, Schmaltz D, Stöckle M, Jocham D, et al. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res. 2006;66:8250–7.PubMedGoogle Scholar
  64. 64.
    Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res. 2011;71:2411–6.PubMedGoogle Scholar
  65. 65.
    Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol. 2010;11:373–84.PubMedGoogle Scholar
  66. 66.
    Watts C, West MA, Zaru R. TLR signalling regulated antigen presentation in dendritic cells. Curr Opin Immunol. 2010;22:124–30.PubMedGoogle Scholar
  67. 67.
    Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature. 2006;440:808–12.PubMedGoogle Scholar
  68. 68.
    Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science. 2010;327:291–5.PubMedCentralPubMedGoogle Scholar
  69. 69.
    Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev. 2007;220:47–59.PubMedGoogle Scholar
  70. 70.
    Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, Miyake K, et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol. 2008;10:1349–55.PubMedGoogle Scholar
  71. 71.
    Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009;457:102–6.PubMedCentralPubMedGoogle Scholar
  72. 72.
    Thompson AV, Locarnini SA. Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response. Immunol Cell Biol. 2007;85:435–45.PubMedGoogle Scholar
  73. 73.
    Kato H, Takahasi K, Fujita T. RIG-I-like receptors: cytoplasmic sensors for non-self RNA. Immunol Rev. 2011;243:91–8.PubMedGoogle Scholar
  74. 74.
    Poeck H, Besch R, Maihoefer C, Renn M, Tormo D, Morskaya SS, et al. 5′-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med. 2008;14:1256–63.PubMedGoogle Scholar
  75. 75.
    Kübler K, Gehrke N, Riemann S, Böhnert V, Zillinger T, Hartmann E, et al. Targeted activation of RNA helicase retinoic acid-inducible gene-I induces proimmunogenic apoptosis of human ovarian cancer cells. Cancer Res. 2010;70:5293–304.PubMedGoogle Scholar
  76. 76.
    Ting JY, Duncan JA, Lei Y. How the noninflammasome NLRs function in the innate immune system? Science. 2010;327:286–90.PubMedCentralPubMedGoogle Scholar
  77. 77.
    Chen G, Shaw MH, Kim YG, Nuñez G. NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol. 2009;4:365–98.PubMedGoogle Scholar
  78. 78.
    Da Silva Correia J, Miranda Y, Austin-Brown N, Hsu J, Mathison J, Xiang R, et al. Nod1-dependent control of tumor growth. Proc Natl Acad Sci U S A. 2006;103:1840–5.PubMedCentralPubMedGoogle Scholar
  79. 79.
    Chen GY, Shaw MH, Redondo G, Núñez G. The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res. 2008;68:10060–7.PubMedCentralPubMedGoogle Scholar
  80. 80.
    Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140:821–32.PubMedGoogle Scholar
  81. 81.
    Allen IC, TeKippe EM, Woodford RT, Uronis JM, Holl EK, Rogers AB, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med. 2010;207:1045–56.PubMedCentralPubMedGoogle Scholar
  82. 82.
    Chow MT, Sceneay J, Paget C, Wong CF, Duret H, Tschopp J, et al. NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases. Cancer Res. 2012;72:5721–32.PubMedGoogle Scholar
  83. 83.
    Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature. 2009;461:282–6.PubMedCentralPubMedGoogle Scholar
  84. 84.
    Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009;15:1170–8.PubMedGoogle Scholar
  85. 85.
    Makin G, Dive C. Apoptosis and cancer chemotherapy. Trends Cell Biol. 2001;11:S22–6.PubMedGoogle Scholar
  86. 86.
    Pervaiz S. Anti-cancer drugs of today and tomorrow: are we close to making the turn from treating to curing cancer? Curr Pharm Des. 2002;8:1723–34.PubMedGoogle Scholar
  87. 87.
    Hanayama R, Tanaka M, Miwa K, Shinohara A, Iwamatsu A, Nagata S. Identification of a factor that links apoptotic cells to phagocytes. Nature. 2002;417:182–7.PubMedGoogle Scholar
  88. 88.
    Nakano T, Ishimoto Y, Kishino J, Umeda M, Inoue K, Nagata K, et al. Cell adhesion to phosphatidylserine mediated by a product of growth arrest-specific gene 6. J Biol Chem. 1997;272:29411–4.PubMedGoogle Scholar
  89. 89.
    Miyanishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S. Identification of Tim4 as a phosphatidylserine receptor. Nature. 2007;450:435–9.PubMedGoogle Scholar
  90. 90.
    Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med. 2010;2:63–94.Google Scholar
  91. 91.
    Okazawa H, Motegi S, Ohyama N, Ohnishi H, Tomizawa T, Kaneko Y, et al. Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system. J Immunol. 2005;174:2004–11.PubMedGoogle Scholar
  92. 92.
    Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, et al. The CD47-signal regulatory protein alpha (SIRPα) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012;109:6662–7.PubMedCentralPubMedGoogle Scholar
  93. 93.
    Jinushi M, Sato M, Kanamoto A, Itoh A, Nagai S, Koyasu S, et al. Milk fat globule epidermal growth factor-8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms. J Exp Med. 2009;206:1317–26.PubMedCentralPubMedGoogle Scholar
  94. 94.
    Geijtenbeek TH, Gringhuis SI. Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol. 2009;9:465–79.PubMedGoogle Scholar
  95. 95.
    Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 2001;194:769–79.PubMedCentralPubMedGoogle Scholar
  96. 96.
    Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449:419–26.PubMedGoogle Scholar
  97. 97.
    Sancho D, Joffre OP, Keller AM, Rogers NC, Martínez D, Hernanz-Falcón P, et al. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature. 2009;458:899–903.PubMedCentralPubMedGoogle Scholar
  98. 98.
    Billadeau DD, Leibson PJ. ITAMs versus ITIMs: striking a balance during cell regulation. J Clin Invest. 2002;109:161–8.PubMedCentralPubMedGoogle Scholar
  99. 99.
    Cosman D, Müllberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14:123–33.PubMedGoogle Scholar
  100. 100.
    Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A. Surface NK receptors and their ligands on tumor cells. Semin Immunol. 2006;18:151–8.PubMedGoogle Scholar
  101. 101.
    Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419:734–8.PubMedGoogle Scholar
  102. 102.
    Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol. 2002;169:4098–102.PubMedGoogle Scholar
  103. 103.
    Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005;436:1186–90.PubMedCentralPubMedGoogle Scholar
  104. 104.
    Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, Hayakawa Y. NKG2D function protects the host from tumor initiation. J Exp Med. 2005;202:583–8.PubMedCentralPubMedGoogle Scholar
  105. 105.
    Cantoni C, Bottino C, Vitale M, Pessino A, Augugliaro R, Malaspina A, et al. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med. 1999;189:787–96.PubMedCentralPubMedGoogle Scholar
  106. 106.
    Alvarez-Breckenridge CA, Yu J, Price R, Wojton J, Pradarelli J, Mao H, et al. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med. 2012;18:1827–34.PubMedCentralPubMedGoogle Scholar
  107. 107.
    Glasner A, Ghadially H, Gur C, Stanietsky N, Tsukerman P, Enk J, et al. Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1. J Immunol. 2012;188:2509–15.PubMedGoogle Scholar
  108. 108.
    Bléry M, Olcese L, Vivier E. Early signaling via inhibitory and activating NK receptors. Hum Immunol. 2000;61:51–64.PubMedGoogle Scholar
  109. 109.
    Ruggeri L, Mancusi A, Burchielli E, Capanni M, Carotti A, Aloisi T, et al. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol Dis. 2008;40:84–90.PubMedGoogle Scholar
  110. 110.
    Passweg JR, Huard B, Tiercy JM, Roosnek E. HLA and KIR polymorphisms affect NK-cell anti-tumor activity. Trends Immunol. 2007;28:437–41.PubMedGoogle Scholar
  111. 111.
    Yokoyama WM, Plougastel BM. Immune functions encoded by the natural killer gene complex. Nat Rev Immunol. 2003;3:304–16.PubMedGoogle Scholar
  112. 112.
    Smith KM, Wu J, Bakker AB, Phillips JH, Lanier LL. Ly-49D and Ly-49H associate with mouse DAP12 and form activating receptors. J Immunol. 1998;161:7–10.PubMedGoogle Scholar
  113. 113.
    Orr MT, Sun JC, Hesslein DT, Arase H, Phillips JH, Takai T, et al. Ly49H signaling through DAP10 is essential for optimal natural killer cell responses to mouse cytomegalovirus infection. J Exp Med. 2009;206:807–17.PubMedCentralPubMedGoogle Scholar
  114. 114.
    Cerwenka A, Lanier LL. Ligands for natural killer cell receptors: redundancy or specificity. Immunol Rev. 2001;181:158–69.PubMedGoogle Scholar
  115. 115.
    Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med. 2003;198:557–67.PubMedCentralPubMedGoogle Scholar
  116. 116.
    Castriconi R, Dondero A, Corrias MV, Lanino E, Pende D, Moretta L, et al. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res. 2004;64:9180–4.PubMedGoogle Scholar
  117. 117.
    Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, et al. Costimulation of antitumor immunity by the B7 counter-receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992;71:1093–102.PubMedGoogle Scholar
  118. 118.
    Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellström I, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med. 1994;179:523–32.PubMedGoogle Scholar
  119. 119.
    Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9:562–7.PubMedGoogle Scholar
  120. 120.
    Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003;170:1257–66.PubMedGoogle Scholar
  121. 121.
    Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99:12293–7.PubMedCentralPubMedGoogle Scholar
  122. 122.
    Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol. 2005;17:133–44.PubMedGoogle Scholar
  123. 123.
    Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med. 2006;203:871–81.PubMedCentralPubMedGoogle Scholar
  124. 124.
    Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Net Rev Immunol. 2006;6:836–48.Google Scholar
  125. 125.
    Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208:1989–2003.PubMedCentralPubMedGoogle Scholar
  126. 126.
    Gresser I, Belardelli F. Endogenous type I interferons as a defense against tumors. Cytokine Growth Factor Rev. 2002;13:111–8.PubMedGoogle Scholar
  127. 127.
    Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol. 2005;6:722–9.PubMedGoogle Scholar
  128. 128.
    Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75:163–89.PubMedGoogle Scholar
  129. 129.
    Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107–11.PubMedGoogle Scholar
  130. 130.
    Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137–48.PubMedGoogle Scholar
  131. 131.
    Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell. 1996;84:431–42.PubMedGoogle Scholar
  132. 132.
    Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity. 1994;1:447–56.PubMedGoogle Scholar
  133. 133.
    Stolfi C, Rizzo A, Franzè E, Rotondi A, Fantini MC, Sarra M, et al. Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J Exp Med. 2011;208:2279–90.PubMedCentralPubMedGoogle Scholar
  134. 134.
    Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci. 2012;33:35–41.PubMedCentralPubMedGoogle Scholar
  135. 135.
    Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411:380–4.PubMedGoogle Scholar
  136. 136.
    Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res. 2007;13:4677–85.PubMedGoogle Scholar
  137. 137.
    Jinushi M, Tahara H. Cytokine gene-mediated immunotherapy: current status and future perspectives. Cancer Sci. 2009;100:1389–96.PubMedGoogle Scholar
  138. 138.
    Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, et al. IL-10 elicits IFNγ-dependent tumor immune surveillance. Cancer Cell. 2011;20:781–96.PubMedGoogle Scholar
  139. 139.
    Li MO, Wan YY, Sanjabi S, Robertson AL, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006;24:99–146.PubMedGoogle Scholar
  140. 140.
    Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342:1350–8.PubMedGoogle Scholar
  141. 141.
    Hunter CA, Bermudez L, Beernink H, Waegell W, Remington JS. Transforming growth factor-beta inhibits interleukin-12-induced production of interferon-gamma by natural killer cells: a role for transforming growth factor-beta in the regulation of T cell-independent resistance to Toxoplasma gondii. Eur J Immunol. 1995;25:994–1000.PubMedGoogle Scholar
  142. 142.
    Castriconi R, Cantoni C, Della-Chiesa M, Vitale M, Marcenaro E, Conte R, et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A. 2003;100:4120–5.PubMedCentralPubMedGoogle Scholar
  143. 143.
    Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell. 2008;13:23–35.PubMedCentralPubMedGoogle Scholar
  144. 144.
    Wakefield LM, Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev. 2002;12:22–9.PubMedGoogle Scholar
  145. 145.
    Fricke I, Mirza N, Dupont J, Lockhart C, Jackson A, Lee JH, et al. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res. 2007;13:4840–8.PubMedGoogle Scholar
  146. 146.
    Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, et al. IL-23 promotes tumour incidence and growth. Nature. 2006;442:461–5.PubMedGoogle Scholar
  147. 147.
    Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009;206:1457–64.PubMedCentralPubMedGoogle Scholar
  148. 148.
    Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med. 2009;15:1016–22.PubMedCentralPubMedGoogle Scholar
  149. 149.
    Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature. 2012;491:254–8.PubMedCentralPubMedGoogle Scholar
  150. 150.
    Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol. 2010;40:22–35.PubMedGoogle Scholar
  151. 151.
    Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev. 2002;188:147–54.PubMedGoogle Scholar
  152. 152.
    Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001;193:727–40.PubMedCentralPubMedGoogle Scholar
  153. 153.
    Hume DA, MacDonald KP. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood. 2012;119:1810–20.PubMedGoogle Scholar
  154. 154.
    Kubota Y, Takubo K, Shimizu T, Ohno H, Kishi K, Shibuya M, et al. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med. 2009;206:1089–102.PubMedCentralPubMedGoogle Scholar
  155. 155.
    DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1:54–67.PubMedCentralPubMedGoogle Scholar
  156. 156.
    Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475:222–5.PubMedCentralPubMedGoogle Scholar
  157. 157.
    Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res. 2000;6:3282–9.PubMedGoogle Scholar
  158. 158.
    Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res. 2002;62:1093–102.PubMedGoogle Scholar
  159. 159.
    Locati M, Deuschle U, Massardi ML, Martinez FO, Sironi M, Sozzani S, et al. Analysis of the gene expression profile activated by the CC chemokine ligand 5/RANTES and by lipopolysaccharide in human monocytes. J Immunol. 2002;168:3557–62.PubMedGoogle Scholar
  160. 160.
    Rot A, Von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol. 2004;22:891–928.PubMedGoogle Scholar
  161. 161.
    Lapteva N, Huang XF. CCL5 as an adjuvant for cancer immunotherapy. Expert Opin Biol Ther. 2010;10:725–33.PubMedGoogle Scholar
  162. 162.
    Stormes KA, Lemken CA, Lepre JV, Marinucci MN, Kurt RA. Inhibition of metastasis by inhibition of tumor-derived CCL5. Breast Cancer Res Treat. 2005;89:209–12.PubMedGoogle Scholar
  163. 163.
    Cambien B, Richard-Fiardo P, Karimdjee BF, Martini V, Ferrua B, Pitard B, et al. CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRβ in colorectal carcinoma. PLoS One. 2011;6:28842.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Research Center for Infection-Associated Cancer, Institute for Genetic MedicineHokkaido UniversitySapporoJapan
  2. 2.Division of Immunobiology, Institute for Genetic MedicineHokkaido UniversitySapporoJapan

Personalised recommendations